UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 22, 2015
APPLIED GENETIC TECHNOLOGIES CORPORATION
(Exact name of Registrant as Specified in Its Charter)
|
Delaware |
|
001-36370 |
|
59-3553710 |
|
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
|
|
|
|
|
11801 Research Drive Suite D Alachua, Florida |
|
|
|
32615 |
|
(Address of Principal Executive Offices) |
|
|
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (386) 462-2204
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01. Regulation FD Disclosure.
Copies of the Company’s current investor presentations are attached to this Current Report on Form 8-K as Exhibits 99.1 and 99.2. Copies of these investor presentations are also available on the Company's website.
In accordance with General Instruction B.2 of Form 8-K, the information contained in Item 7.01 of this Current Report on Form 8-K, including the Exhibits attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in Item 7.01 of this Current Report on Form 8-K shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
Description |
|
99.1 99.2 |
Investor presentation entitled “AGTC Analyst and Investor Day, June 22, 2015.” Investor presentation entitled “Visionary Science for Life Changing Cures, 2015.” |
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
APPLIED GENETIC TECHNOLOGIES CORPORATION |
|
|
|
|
|
|
|
|
Date: June 22, 2015 |
|
By: |
/s/ Lawrence E. Bullock |
|
|
|
|
|
|
Lawrence E. Bullock |
|
|
|
|
|
Chief Financial Officer |
3
|
Exhibit No. |
Description |
|
99.1 99.2 |
Investor presentation entitled “AGTC Analyst and Investor Day, June 22, 2015.” Investor presentation entitled “Visionary Science for Life Changing Cures, 2015.”
|
4